黑料网

Pain genetics; Epigenetics; Nociception; Chronic pain; Gene-environment interactions

Introduction

Pain, often considered the body's alarm system, serves a fundamental role in alerting individuals to potential harm or injury, thereby facilitating appropriate protective responses essential for survival. Despite its universality and significance, the mechanisms underlying pain perception remain intricately complex and, to a large extent, enigmatic. Recent advancements in scientific research have shed light on the pivotal roles played by genetic and epigenetic factors in shaping the experience of pain. Genetic variations within the human genome contribute significantly to the variability observed in pain sensitivity among individuals. Through extensive studies examining the genetic architecture of pain perception, researchers have identified a myriad of candidate genes implicated in various aspects of pain processing pathways [1,2]. These genes encode proteins such as neurotransmitters, ion channels, and receptors that are integral to the transmission and modulation of pain signals within the nervous system. Variations in these genes, whether single nucleotide polymorphisms (SNPs) or structural variations, can profoundly influence an individual's susceptibility to pain, dictating their threshold for experiencing pain and their response to analgesic treatments.

In parallel, the burgeoning field of epigenetics has unveiled another layer of complexity in the regulation of pain-related gene expression. Epigenetic modifications, including DNA methylation, histone modifications, and microRNA regulation, serve as dynamic mechanisms for modulating gene activity in response to environmental cues. These modifications, often induced by factors such as stress, injury, or inflammation, can exert profound effects on the transcriptional activity of genes involved in pain processing. Moreover, emerging evidence suggests that epigenetic changes acquired over the lifespan can contribute to the development and persistence of chronic pain conditions, thereby highlighting the intricate interplay between genetic predispositions and environmental influences in shaping pain perception and chronic pain phenotypes [3,4].

Against this backdrop, this review aims to provide a comprehensive overview of the current understanding of pain genetics and epigenetics, with a specific focus on their roles in nociception and chronic pain development. By synthesizing findings from genetic association studies, epigenome-wide association studies (EWAS), and experimental models, this review seek to elucidate the intricate interplay between genetic variations and epigenetic modifications in modulating pain sensitivity and chronic pain susceptibility. Furthermore, by delineating the molecular mechanisms underlying pain modulation, this review aims to inform the development of novel therapeutic strategies aimed at personalized pain management, tailored to individual genetic and epigenetic profiles. Ultimately, a deeper understanding of pain genetics and epigenetics holds the promise of revolutionizing our approach to pain management, offering new avenues for alleviating suffering and improving the quality of life for individuals living with chronic pain conditions [5,6].

Results

Genetic studies have identified numerous candidate genes involved in pain processing pathways, including those encoding neurotransmitters, ion channels, and receptors. Polymorphisms in these genes have been linked to variations in pain sensitivity and susceptibility to chronic pain conditions. Epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs also play crucial roles in regulating gene expression in response to pain stimuli. Dysregulation of epigenetic processes has been implicated in chronic pain states, highlighting their potential as therapeutic targets [7].

Discussion

The interplay between genetics and epigenetics in pain modulation represents a dynamic and intricate relationship, contributing significantly to the variability observed in pain perception among individuals. Genetic predispositions, shaped by inherited variations in DNA sequence, lay the foundation for an individual's baseline susceptibility to pain. These genetic factors encompass a wide array of genes involved in nociceptive signaling, neurotransmitter release, synaptic plasticity, and pain modulation pathways within the central and peripheral nervous systems. However, the expression and function of these genes are not solely dictated by their DNA sequence; rather, they are subject to regulation by epigenetic mechanisms in response to environmental stimuli [8].

Environmental factors, ranging from physical injury and psychological stress to lifestyle habits and social interactions, exert profound influences on pain sensitivity and chronic pain development. These environmental cues can induce epigenetic modifications that dynamically alter the expression of pain-related genes, thereby fine-tuning an individual's pain response. For instance, exposure to chronic stress has been associated with changes in DNA methylation patterns at specific gene loci implicated in pain processing, leading to alterations in pain sensitivity and the development of chronic pain conditions. Similarly, inflammation-induced histone modifications and microRNA dysregulation have been implicated in the pathogenesis of inflammatory pain states, further highlighting the pivotal role of epigenetic regulation in mediating gene-environment interactions in pain modulation [9].

Understanding the intricate interplay between genetic predispositions and epigenetic modifications is paramount for elucidating the mechanisms underlying individual differences in pain perception and chronic pain development. By deciphering the molecular pathways through which genetic and epigenetic factors converge to modulate pain sensitivity, researchers can uncover novel therapeutic targets for pain management. Integrating genetic and epigenetic approaches, such as genome-wide association studies (GWAS) and epigenome-wide association studies (EWAS), holds immense promise for identifying key genetic variants and epigenetic marks associated with pain susceptibility and chronic pain conditions. Moreover, leveraging advanced technologies such as CRISPR-based gene editing and epigenome editing techniques may enable targeted manipulation of pain-related genes and epigenetic modifications, paving the way for precision medicine approaches tailored to individual genetic and epigenetic profiles [10].

Conclusion

Pain genetics and epigenetics represent promising avenues for unravelling the complexity of pain processing mechanisms. Genetic variations and epigenetic modifications contribute to individual differences in pain sensitivity and chronic pain susceptibility. Further research is needed to elucidate the specific genes and epigenetic marks involved in pain modulation and to translate these findings into personalized pain management strategies. By integrating genetic and epigenetic approaches, we can advance our understanding of pain mechanisms and improve clinical outcomes for individuals suffering from chronic pain conditions.

References

1. Mogil JS (2012) . Trends Genet 28: 258-266.

, , Crossref

2. Freidin MB, Tsepilov YA, Palmer M, Karssen LC, Suri P (2019) . Pain 160: 1361-1373.

, ,

3. Vachon-Presseau E, Tétreault P, Petre B, Huang L, Berger SE, et al. (2016) . Brain 139: 1958-1970.

, ,

4. Denk F, McMahon SB, Tracey I (2014) . Nat Neurosci 17: 192-200.

, ,

5. Nestler EJ (2014) . Neuropharmacology 76: 259-268.

, , Crossref

6. Denk F, McMahon SB, Tracey I (2014) . Nat Neurosci 17: 192-200.

, , Crossref

7. Wand BM, Parkitny L, O'Connell NE, Luomajoki H, McAuley JH, Thacker M, Di Pietro F (2011) . Man Ther 16: 15-20.

, ,

8. Nijs J, Meeus M, Versijpt J, Moens M, Bos I, et al. (2012) Expert Opin Ther Targets16: 1237-1251.

, ,

9. Macedo LG, Saragiotto BT, Yamato TP, Costa LOP, Menezes Costa LC, et al. (2016) . Cochrane Database Syst Rev 2.

, ,

10. Slade SC, Keating JL, Georgiou-Karistianis N (2013) . BMC Neurol 13: 1-13.

, ,